Brain Cancer

Metastatic Breast Cancer

Breast Cancer

Colorectal Cancer

Gastric Cancers

Liver Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancer

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head and Neck Cancers

Graft-Vs-Host Disease

Leukemia

Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematology

Lung Cancer

Pediatric Cancer

Sarcomas

Melanoma

Skin Cancer

Data from a research database link ctDNA positivity in early breast cancer with poorer survival and higher recurrence risk.

Real-World Data Tie Early Breast Cancer ctDNA to Recurrence, Lower OS

ALLO-316 showed significant activity and safety in patients with metastatic CD70-positive clear cell renal cell carcinoma.

Allogenic CAR T-Cell Agent Safe, Active in Heavily Pretreated RCC

Adjuvant aspirin did not reduce recurrence or improve survival in patients with CRC liver metastases, phase 3 data showed at the 2025 ASCO Meeting.

No Survival, Recurrence Benefit With Aspirin in CRC Liver Metastases

The combination of relacorilant and nab-paclitaxel improved survival in platinum-resistant ovarian cancer following a break from platinum-based chemo.

Relacorilant Combo Sustains Ovarian Cancer Benefit Post Platinum Break

News

Latest News

FDA News

Adverse Event Management

Supportive Care

Disparities in Cancer Care

Drug Safety

Radiation Oncology

Survivorship 

Practice Management

Prevention

Contributors

Media

Expert Connections

Morning Rounds

The Vitals

Podcasts

Videos

Between the Lines

From All Angles

Meeting of the Minds

Training Academy

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Continuing Education

Resources

Case-Based Digest 

Rx Road Map

Webinars

Cancer Summary Slides

MPN Symptom Management

Events

Subscribe

Partners

Erika Hamilton is the director of breast and gynecologic cancer research at Sarah Cannon Research Institute in Nashville, Tennessee.

Bridget Hoyt is the assistant editor for Oncology Nursing News. She earned her BA in communication studies at Rider University with a minor in public relations. She can be reached at 

New therapies in breast cancer, particularly ADCs, present unique safety profiles for nurses to be aware of, according to Erika Hamilton, MD.

Safety Profiles to Look Out For in New Breast Cancer Treatments

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for 

. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Those who took dexamethasone reported higher levels of satisfaction than patients on placebo.

Olanzapine/Triplet Cuts Chemo-Induced Nausea, Vomiting in Breast Cancer

Panitumumab plus FOLFIRINOX or mFOLFOX6 failed to yield meaningful responses in liver-limited, RAS/BRAF wild-type unresectable mCRC.

Panitumumab-Based Chemo Falls Short in Liver-Limited mCRC

Oncology Nursing News connects oncology nurses and APPs with updates on therapy advances, side effect management, and patient-centered cancer care.

About Us

Editorial Board

Contact Us

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Advertise

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News – Clinical Insights for Cancer Care Nurses

Facebook

LinkedIn

Specialty

Advanced Practice Providers

Clinical

Gynecologic Cancer

Immunotherapy

Nurse Navigation

Quality Improvement

1rem

In TP53 wild-type advanced or recurrent endometrial cancer, selinexor improved multiple time-to-event outcomes vs placebo.

Selinexor Maintenance Offers Durable Benefit in Advanced Endometrial Cancer

Olanzapine plus an antiemetic shows potential in preventing RINV while reducing other adverse events such as depression, appetite loss, and insomnia.

Olanzapine May Reduce Nausea, Vomiting From Radiation

Oncology nurses can enhance endometrial cancer recovery by fostering strong social support networks and improving communication with the patient.

Opinion: Social Support is Key to Endometrial Cancer Recovery

Biocartis announced the launch of its real-time quantitative polymerase chain reaction assay to detect POLE and POLD1 mutations in endometrial cancer.

Biocartis Launches qPCR POLE/POLD1 Mutational Assay

The safety and efficacy of dostarlimab plus chemotherapy in patients with advanced endometrial cancer were confirmed by results of a real-world study.

Real-World Data Verify Safety, Efficacy of Dostarlimab/Chemo in Endometrial Cancer

Closing their discussion, the panel shares advice for new nurse practitioners caring for patients who have endometrial cancer.

Peer Exchange

Advice for New Nurse Practitioners Working With Patients With Endometrial Cancer

The panel shares the most critical unmet needs for patients with endometrial cancer.

Greatest Unmet Needs for Patients with Endometrial Cancer

Kimberly A. Spickes, CNP, discusses how often patients with endometrial cancer have dose reductions or interruptions at her institution, and who is involved in the decision to dose-reduce.

Discussing Dose Reductions and Interruptions with Patients on Therapy for Endometrial Cancer

Nurse Practitioner Kimberly Halla explains the proactive measures she takes to ensure patients with endometrial cancer are prepared to experience and manage the adverse effects of treatment.

Proactive Adverse Effect Management for Patients on Therapy for Endometrial Cancer

Kimberly A. Spickes, CNP, details the adverse events she sees with combination lenvatinib and pembrolizumab treatment for recurrent endometrial cancer.

Adverse Events Seen With Combination Lenvatinib and Pembrolizumab for Recurrent Endometrial Cancer

Kimberly Halla, NP, describes the standards for monitoring patients on therapy for recurrent endometrial cancer, including how often patients are seen in-person.

Monitoring Patients on Therapy for Recurrent Endometrial Cancer

The panel explains how to educate patients on the adverse effects they may experience with chemotherapy, their options for management, and the importance of encouraging patients to contact their care team.

Educating Patients With Endometrial Cancer on Treatment-Related Adverse Events

The panel reviews the second-line treatment options for patients with recurrent endometrial cancer.

Treatment Options for Patients with Recurrent Endometrial Cancer

Nurse Practitioner Kathleen Lutz talks about the efficacy of chemotherapy in patients with endometrial cancer, and how she discusses the chance of disease recurrence with patients.

Efficacy of Chemotherapy in Patients with Advanced Endometrial Cancer

Continuing her discussion, Kathleen highlights the most common adverse events she sees in patients treated with chemotherapy for advanced endometrial cancer who are unfit for surgery.

Endometrial Cancer

Latest News

Latest Conference Coverage